Trials / Conditions / Hematological Disease

Hematological Disease

14 registered clinical trials studyying Hematological Disease — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Hematological Disorder in Patients With Angiodysplasia NCT06050798	Assiut University	—
Unknown	Some Hematological Profile in Children With Chronic Kidney Disease NCT06143098	Assiut University	—
Unknown	Hetrombopag for the Enhancement of Platelet Engraftment After Allogeneic Hematopoietic Stem Cell Transplantati NCT05727917	Institute of Hematology & Blood Diseases Hospital, China	N/A
Completed	AI Algorithms to Automate the TMI by VMAT Optimization Using WB-CT/MRI and Synthetic WB-CT - The AuToMI Projec NCT04976205	Istituto Clinico Humanitas	N/A
Completed	XIENCE 28 Global Study NCT03355742	Abbott Medical Devices	N/A
Completed	CMV-CTL for the Treatment of CMV Infection After HSCT NCT03004261	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	Phase 4
Completed	URMC Related Haplo-identical Donor BMT NCT02660281	University of Rochester	Phase 1
Completed	Randomized Trial:the Effect of Liquid Food on the Intake of Energy and Protein in Malignant Hematologic Patien NCT02447237	Jens Rikardt Andersen	N/A
Unknown	Assessing the Effect of Contact Isolation on Nosocomial Colonization With ESBL-EC in German Hematology/Oncolog NCT02456818	University of Cologne	—
Completed	A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative NCT02158858	Constellation Pharmaceuticals	Phase 1 / Phase 2
Unknown	Registry of Febrile Neutropenia and Invasive Fungal Infections NCT01684189	Chang Gung Memorial Hospital	—
Terminated	Cord Blood Transplantation for Patients With Cancer NCT01359254	University of Chicago	Phase 2
Unknown	Exercise Following Autologous Peripheral Blood Stem Cell Transplantation NCT00883961	Charite University, Berlin, Germany	Phase 3
Completed	Safety and Tolerability of CHR-2845 to Treat Haematological Diseases or Lymphoid Malignancies NCT00820508	Chroma Therapeutics	Phase 1